Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19264696 | 0.86 | SLC6A3 (0.40) | SLC6A3SLC6A2SLC6A4ACHE | |
| SCHEMBL14752782 | 0.85 | MAPT (0.40) | TP53RAB9AKDM4EALDH1A1 | |
| SCHEMBL29013549 | 0.77 | SLC6A3 (0.42) | SLC6A3SLC6A2SLC6A4ACHE | |
| SCHEMBL8648768 | 0.76 | CA1 (0.52) | SLC6A3SLC6A2SLC6A4KDM4EALDH1A1 | |
| SCHEMBL31384688 | 0.76 | SLC6A3 (0.45) | SLC6A3SLC6A2SLC6A4ACHE | |
| SCHEMBL8636289 | 0.74 | SLC6A3 (0.53) | SLC6A3SLC6A2SLC6A4ACHE | |
| SCHEMBL17373971 | 0.73 | TP53 (0.37) | TP53RAB9AKDM4EALDH1A1 | |
| SCHEMBL5656613 | 0.73 | SLC6A3 (0.45) | SLC6A3SLC6A2SLC6A4ACHEKDM4E | |
| SCHEMBL11871305 | 0.72 | TP53 (0.39) | TP53RAB9A | |
| SCHEMBL12777592 | 0.72 | NLRP3 (0.41) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230302162-A1 | RADIOLABELED DARAPLADIB AND ANALOGS THEREOF AND THEIR USE AS IMAGING COMPOUNDS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2023-09-28 | — | — | US | disclosed |
| US-11583596-B2 | Radiolabeled Darapladib and analogs thereof and their use as imaging compounds | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2023-02-21 | — | — | US | disclosed |
| EP-3687980-B1 | RADIOLABELED DARAPLADIB, ANALOGS THEREOF AND THEIR USE AS IMAGING COMPOUNDS | INST NAT SANTE RECH MED (FR) | 2022-01-19 | — | — | EP | disclosed |
| US-20200276337-A1 | RADIOLABELED DARAPLADIB AND ANALOGS THEREOF AND THEIR USE AS IMAGING COMPOUNDS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2020-09-03 | — | — | US | disclosed |
| WO-2019063634-A1 | RADIOLABELED DARAPLADIB AND ANALOGS THEREOF AND THEIR USE AS IMAGING COMPOUNDS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-04-04 | — | — | WO | disclosed |
| EP-2571857-B1 | PROCESS FOR THE PREPARATION OF PYRIMIDINONE COMPOUNDS | GLAXO GROUP LTD (GB) | 2017-08-23 | — | — | EP | disclosed |
| EP-2571857-B1 | PROCESS FOR THE PREPARATION OF PYRIMIDINONE COMPOUNDS | GLAXO GROUP LTD (GB) | 2017-08-23 | — | — | EP | disclosed |
| US-9725420-B2 | Processes | GLAXO GROUP LIMITED (GB) | 2017-08-08 | — | — | US | disclosed |
| US-9725420-B2 | Processes | GLAXO GROUP LIMITED (GB) | 2017-08-08 | — | — | US | disclosed |
| US-9725420-B2 | Processes | GLAXO GROUP LIMITED (GB) | 2017-08-08 | — | — | US | disclosed |
| US-20160347720-A1 | NOVEL PROCESSES | GLAXO GROUP LIMITED (GB) | 2016-12-01 | — | — | US | disclosed |
| US-9447052-B2 | Processes for preparing pyrimidine compounds | GLAXO GROUP LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-9447052-B2 | Processes for preparing pyrimidine compounds | GLAXO GROUP LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-9447052-B2 | Processes for preparing pyrimidine compounds | GLAXO GROUP LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| EP-2571857-A1 | NOVEL PROCESSES | Glaxo Group Limited (GB) | 2013-03-27 | — | — | EP | disclosed |
| US-20130060028-A1 | NOVEL PROCESSES | GLAXO GROUP LIMITED (GB) | 2013-03-07 | — | — | US | disclosed |
| US-20130060028-A1 | NOVEL PROCESSES | GLAXO GROUP LIMITED (GB) | 2013-03-07 | — | — | US | disclosed |
| US-20130060028-A1 | NOVEL PROCESSES | GLAXO GROUP LIMITED (GB) | 2013-03-07 | — | — | US | disclosed |
| WO-2011146494-A1 | NOVEL PROCESSES | GLAXO GROUP LIMITED (GB) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011146494-A1 | NOVEL PROCESSES | GLAXO GROUP LIMITED (GB) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130060028-A1 | NOVEL PROCESSES | CYP11B1, CYP27A1, CYP11B2 | SLC6A3 4857/4885SLC6A2 4762/4885SLC6A4 4820/4885 |
| US-11583596-B2 | Radiolabeled Darapladib and analogs thereof and their use as imaging compounds | PLA2G4B, PLA2G1B, PLA2G12B | SLC6A3 3613/4885SLC6A2 3479/4885SLC6A4 4424/4885 |
| US-20160347720-A1 | NOVEL PROCESSES | CYP11B1, CYP27A1, CYP11B2 | SLC6A3 4857/4885SLC6A2 4762/4885SLC6A4 4820/4885 |
| US-20230302162-A1 | RADIOLABELED DARAPLADIB AND ANALOGS THEREOF AND THEIR USE AS IMAGING COMPOUNDS | PLA2G4B, PLA2G1B, PLA2G12B | SLC6A3 3613/4885SLC6A2 3479/4885SLC6A4 4424/4885 |
| US-20200276337-A1 | RADIOLABELED DARAPLADIB AND ANALOGS THEREOF AND THEIR USE AS IMAGING COMPOUNDS | PLA2G4B, PLA2G1B, PLA2G12B | SLC6A3 3613/4885SLC6A2 3479/4885SLC6A4 4424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.